This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
by Zacks Equity Research
Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
by Zacks Equity Research
Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
Viatris' (VTRS) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) reports lower-than-expected fourth-quarter financial results, as both earnings and sales miss estimates. Stock declines in pre-market.
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Perrigo (PRGO) Q4 Earnings Top, Sales Lag Estimates, Misses View
by Zacks Equity Research
Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations. Stock price drops 10% after this announcement.
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
by Zacks Equity Research
Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.
BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales
by Zacks Equity Research
BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review
by Zacks Equity Research
Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Adicet (ACET) Stock Rallies 130% in a Month: Here's Why
by Zacks Equity Research
Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024.
Adicet Bio, Inc. (ACET) Upgraded to Buy: Here's Why
by Zacks Equity Research
Adicet Bio, Inc. (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
by Zacks Equity Research
Here is how Adicet Bio, Inc. (ACET) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.
Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus
by Zacks Equity Research
Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.